Clinical Trials Logo

Sleep Wake Disorders clinical trials

View clinical trials related to Sleep Wake Disorders.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06415981 Active, not recruiting - Sleep Apnea Clinical Trials

Proof-of-Concept Study to Determine the Flow Changes When Stimulating Two Neural Targets for the Treatment of Obstructive Sleep Apnea

Start date: December 21, 2022
Phase: N/A
Study type: Interventional

This proof-of-concept study will evaluate the impact of surgically placing and stimulating the hypoglossal nerve and/or a second neural target Ansa Cervicalis, with a set of off-the-shelf electrode arrays.

NCT ID: NCT06283017 Active, not recruiting - Sleep Apnea Clinical Trials

Evaluation of the Effects of Hypoglossal Nerve Stimulation in Humans With Obstructive Sleep Apnea

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

This proof-of-concept study is being performed to evaluate whether the hypoglossal nerve can be stimulated using a small series of electrodes placed surgically via a percutaneous approach. Minimally invasive off the shelf medical devices will be used and observation of the characteristic physiological responses to stimulation of the HGN, will be assessed.

NCT ID: NCT05917379 Active, not recruiting - Depression Clinical Trials

The Safety and Efficacy of FMT in Patients With CID

Start date: October 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to learn about The safety and efficacy of fecal microbiota transplantation in patients with chronic insomnia disorder. The main question[s] it aims to answer are: - Safety of the FMT oral capsule pathway in the clinical treatment of chronic insomnia - Effectiveness of the FMT oral capsule route for patients with chronic insomnia Participants in the intervention group will be given FMT by boral capsule pathway, and in the control group will be given the same appearance capsules containing vitamins. Researchers will compare the sleep status(PSQI and PSG)of the patients in both groups.

NCT ID: NCT05812443 Active, not recruiting - Quality of Life Clinical Trials

Assessment of Sleep Quality and Mental Health After Using Meditation

Start date: April 10, 2023
Phase: N/A
Study type: Interventional

This is a randomized controlled trial that intends to verify the effectiveness of the daily practice of meditation before going to sleep for the improvement of sleep, stress, mental health and quality of life of people with sleep problems.

NCT ID: NCT05805657 Active, not recruiting - Sleep Disorder Clinical Trials

Implementing and Sustaining a Sleep Treatment to Improve Community Mental Health Part 2: Train-the-Trainer

Start date: December 14, 2020
Phase: N/A
Study type: Interventional

The train-the-trainer (TTT) approach is a promising method of sustaining training efforts in community mental health centers (CMHCs). This study will test the implementation and effectiveness outcomes of a sleep treatment delivered by CMHC providers who are trained and supervised within CMHCs via TTT. The investigators will test two versions of the sleep treatment, a "Standard" version and an "Adapted" version that has been adapted using theory, data and stakeholder inputs to improve the fit for SMI patients treated in community mental health centers.

NCT ID: NCT05489159 Active, not recruiting - Insulin Resistance Clinical Trials

Sleep and IR in Transgender Adolescents

ATP
Start date: October 12, 2022
Phase:
Study type: Observational

Disordered sleep is a health issue with significant impacts on physical and psychological well-being that has increased in prevalence, but its impact on transgender adolescents has not been fully quantified. While there is found to be an impact of sex steroids on sleep, and sex-dependent differences in the impact of sleep duration and quality on insulin resistance (IR), there is limited available information regarding the impact of Gender Affirming Hormone Therapy (GAHT) for transgender individuals on sleep and IR. Our study aims to quantify the impacts of GAHT on sleep and IR in the pediatric transgender population as well as determine the degree of correlation of sleep to IR in this population.

NCT ID: NCT05208008 Active, not recruiting - Stress, Emotional Clinical Trials

Effect of Owning a Service Dog on Military Veterans With PTSD

Start date: January 17, 2022
Phase:
Study type: Observational

The study aims to investigate the effects of a service dog on military veterans with post traumatic stress syndrome (PTSD). The investigators will use non-invasive measures of the physiological responses, data obtained via dairy keeping, accelerometer data estimating activity and sleep patterns, and baseline information including psychological measures validated for this specific population.

NCT ID: NCT05062161 Active, not recruiting - Hypertension Clinical Trials

Sleep Duration and Blood Pressure During Sleep

Start date: September 30, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the impact that sleep duration has on blood pressure (BP) levels during sleep. The investigator will examine the effect of an 8-week sleep hygiene/extension intervention vs. control on sleep BP.

NCT ID: NCT04992676 Active, not recruiting - Clinical trials for Coronary Artery Disease

Comorbid Insomnia and Sleep Disordered Breathing in Patients Undergoing Cardiac Rehabilitation

Start date: August 19, 2021
Phase:
Study type: Observational

The purpose of this research is to determine how frequently sleep disorders such as sleep disordered breathing and insomnia occur in patients with coronary artery disease enrolled in cardiac rehabilitation. By reviewing results of a variety of tests, we also hope to learn more about the cardiovascular effects on people who may have these conditions.

NCT ID: NCT04986995 Active, not recruiting - Parkinson Disease Clinical Trials

OpicApone Sleep dISorder

OASIS
Start date: June 9, 2021
Phase: Phase 4
Study type: Interventional

The aim of this study is to To investigate in an exploratory manner the efficacy of 50 mg opicapone when administered with the existing treatment of levodopa (L-dopa) plus a dopa decarboxylase inhibitor (DDCI), in Parkinson's disease (PD) patients with end-of-dose motor fluctuations and associated sleep disorders